Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award
07 Fevereiro 2019 - 12:15PM
Dr. Johnson Recognized for Advancing
Scientific Understanding of Alcoholism and its
Prevention
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage
biopharmaceutical company focused on the development of treatments
for addiction, congratulates its Chairman, Dr. Bankole
Johnson, DSc, MD, for being named as the 2019 recipient of the
American Society of Addiction Medicine’s (ASAM) Brinkley Smithers
Distinguished Scientist Award.
The award recognizes and honors an individual who
has made highly meritorious contributions in advancing the
scientific understanding of alcoholism, its prevention and
treatment. The Award and lecture will be presented at ASAM’s
50th Annual Conference in April, 2019.
“This award from the American Society of Addiction
Medicine is a great honor for Dr. Johnson, and it highlights how
his leadership is bringing progress in the quest to find clinically
based solutions for addiction to help the millions struggling with
Alcohol Use Disorder (AUD),” commented William Stilley, CEO of
Adial Pharmaceuticals. “As recently reported in The Lancet, one of
the world’s leading medical journals, alcohol is the number one
cause of death globally among both men and women ages 15 to 49
years. Dr. Johnson’s work and leadership in the field is aimed to
specifically address this enormous issue and this recognition
highlights a career of dedication to finding answers for those
suffering from AUD.”
The ASAM, founded in 1954, is a professional
medical society representing more than 6,000 physicians, clinicians
and associated professionals in the field of addiction medicine.
The R. Brinkley Smithers Distinguished Scientist Award and Lecture
was established by ASAM in 1995 as a lasting tribute to R. Brinkley
Smithers, who influenced American alcoholism policy, theory and
treatment.
About Adial Pharmaceuticals,
Inc.
Adial Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on the development of treatments
for addictions. The Company’s lead investigational new drug
candidate, AD04, is a genetically targeted therapeutic agent for
the treatment of Alcohol Use Disorder (“AUD”). A Phase 2b clinical
trial of AD04 for the treatment of AUD showed promising results in
reducing frequency of drinking, quantity of drinking and heavy
drinking (all with statistical significance), and no overt safety
concerns (there were no statistically significant serious adverse
events reported). The Company plans to commence a Phase 3 clinical
trial using AD04 for the potential treatment of AUD in subjects
with certain target genotypes, which are to be identified using the
Company’s proprietary companion diagnostic genetic test. AD04 is
also believed to have the potential to treat other addictive
disorders such as opioid use disorder, gambling, and obesity.
Forward Looking Statements
This communication contains certain
“forward-looking statements” within the meaning of the U.S. federal
securities laws. Such statements are based upon various facts and
derived utilizing numerous important assumptions and are subject to
known and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements are based upon current beliefs,
expectations and assumptions and include statements regarding plans
to commence a Phase 3 clinical trial using AD04 for the potential
treatment of AUD in subjects with certain target genotypes. Any
forward-looking statements included herein reflect our current
views, and they involve certain risks and uncertainties, including,
among others, our ability commence the Phase 3 clinical trials in
the first half of 2019, the ability of AD04 therapy to
perform as designed, to demonstrate safety and efficacy, as well as
results that are consistent with prior results, the ability to
enroll patients and complete the clinical trials on time and
achieve desired results and benefits, our ability to obtain
regulatory approvals for commercialization of product candidates or
to comply with ongoing regulatory requirements, regulatory
limitations relating to our ability to promote or
commercialize our product candidates for specific indications,
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products, our ability
to maintain our license agreements, the continued maintenance and
growth of our patent estate, our ability to establish and maintain
collaborations, our ability to obtain or maintain the capital or
grants necessary to fund our research and development activities,
and our ability to retain our key employees or maintain our Nasdaq
listing. These risks should not be construed as exhaustive and
should be read together with the other cautionary statements
included in our registration statement on Form S-1 that we have
filed with the SEC and the final prospectus and our Current Report
on Form 10-Q for the quarter ended September 30, 2018. Any
forward-looking statement speaks only as of the date on which it
was initially made. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events, changed circumstances or otherwise,
unless required by law.
Contact:
Crescendo Communications, LLC David Waldman / Natalya Rudman
Tel: 212-671-1021 Email: dwaldman@crescendo-ir.com
Adial Pharmaceuticals (NASDAQ:ADIL)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024